AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25098661 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinged models
Number of subjects: 17
Study 25098661 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhinged brace
Number of subjects: 17
Study 22472272 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 27
Study 22472272 — intervention group
Group type: COMPARATOR
Intervention: Control (no PRP)
Number of subjects: 27
Study 20335369 — intervention group
Group type: EXPERIMENTAL
Intervention: CERA 6.3 μg/kg
Number of subjects: 0
Study 20335369 — intervention group
Group type: EXPERIMENTAL
Intervention: CERA 9 μg/kg
Number of subjects: 0
Study 20335369 — intervention group
Group type: EXPERIMENTAL
Intervention: CERA 12 μg/kg
Number of subjects: 0
Study 20335369 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa (6.75 μg/kg every 3 weeks or 2.25 μg/kg weekly)
Number of subjects: 0
Study 17926466 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (LF) 100 mg/day for 3 days then 20 mg/day for 6 months
Number of subjects: 58
Study 17926466 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (LF)
Number of subjects: 58
Study 15602683 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 0
Study 11943259 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg plus Vitamin E 400 IU, each twice daily (n=19)
Number of subjects: 40
Study 9794352 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg once daily for 8 weeks
Number of subjects: 365
Study 9794352 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 32 mg once daily for 8 weeks
Number of subjects: 365
Study 9794352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 7892448 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIO-enhanced SE and FLASH sequences
Number of subjects: 15
Study 7892448 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced T2-weighted SE sequences
Number of subjects: 15
Study 7892448 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced images
Number of subjects: 15
Study 2128265 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Intralipid (MCT)
Number of subjects: 20
Study 2128265 — intervention group
Group type: COMPARATOR
Intervention: 10% Lipofundin (LCT)
Number of subjects: 20
Study 110184 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF 600 mg
Number of subjects: 822
Study 110184 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF 750 mg
Number of subjects: 822
Study 110184 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF 450 mg
Number of subjects: 822
Study 110184 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF-EMB therapy (300 mg INH and 15 mg EMB per kg)
Number of subjects: 822
Study 110184 — intervention group
Group type: COMPARATOR
Intervention: 12 months of chemotherapy after sputum conversion
Number of subjects: 822
Study 110184 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF-INH therapy
Number of subjects: 822
Study 31492784 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance and impact training (HiRIT)
Number of subjects: 160
Study 31492784 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity exercise programme (control)
Number of subjects: 160
Study 27628062 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (2.0 mg) administered as three monthly doses followed by injections every 2 months
Number of subjects: 40
Study 25827058 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO, 15 mg for 6 weeks, then 30 mg daily)
Number of subjects: 42
Study 25827058 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 42
Study 24246211 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg daily plus celecoxib 200 mg daily (study group)
Number of subjects: 82
Study 24246211 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin 4 mg daily alone (control group)
Number of subjects: 82
Study 21575919 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (4 mg, n=10)
Number of subjects: 30
Study 21575919 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg, n=10)
Number of subjects: 30
Study 21575919 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg) + Verapamil (180 mg, n=10)
Number of subjects: 30
Study 19627355 — intervention group
Group type: EXPERIMENTAL
Intervention: Tin-containing fluoride solutions (400 ppm Sn2+, 1,500 ppm F-, pH 4.5)
Number of subjects: 0
Study 19627355 — intervention group
Group type: EXPERIMENTAL
Intervention: Tin-containing fluoride solutions (1,400 ppm Sn2+, 1,500 ppm F-, pH 4.5)
Number of subjects: 0
Study 19627355 — intervention group
Group type: EXPERIMENTAL
Intervention: Tin-containing fluoride solutions (2,100 ppm Sn2+, 1,500 ppm F-, pH 4.5)
Number of subjects: 0
Study 19627355 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (no treatment)
Number of subjects: 0
Study 19627355 — intervention group
Group type: EXPERIMENTAL
Intervention: Test solutions without demineralization (twice daily)
Number of subjects: 0
Study 16417535 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) at doses up to 2000 mg/day
Number of subjects: 14
Study 16417535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15573840 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectacles lenses with a prismatic correction of low power (5‐7 prismatic dioptres) in the better eye
Number of subjects: 28
Study 15573840 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prismatic correction)
Number of subjects: 28
Study 11244453 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise training (40% VO(2max), n=7)
Number of subjects: 23
Study 11244453 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (70% VO(2max), n=8)
Number of subjects: 23
Study 11244453 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group (n=8)
Number of subjects: 23
Study 11244453 — intervention group
Group type: COMPARATOR
Intervention: Lean subjects (n=6)
Number of subjects: 23
Study 9135350 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 102
Study 9135350 — intervention group
Group type: COMPARATOR
Intervention: propofol
Number of subjects: 102
Study 8193987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propafenone 1.5 mg/kg infused over 5 mins
Number of subjects: 10
Study 8193987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propafenone
Number of subjects: 10
Study 8193987 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-tilt measurements
Number of subjects: 10
Study 2822924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular deferoxamine 100 mg
Number of subjects: 11
Study 2822924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29913174 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg, initiated at 13-25 weeks' gestation)
Number of subjects: 2543
Study 29913174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2543
Study 27771739 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy
Number of subjects: 220
Study 27771739 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 220
Study 24845164 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana eCHECKUP TO GO
Number of subjects: 123
Study 24845164 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 123
Study 23294659 — intervention group
Group type: EXPERIMENTAL
Intervention: Resonant breathing biofeedback training (5 weekly sessions)
Number of subjects: 36
Study 23294659 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study 20472745 — intervention group
Group type: EXPERIMENTAL
Intervention: Akreos Adapt IOL
Number of subjects: 122
Study 20472745 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof SA60AT IOL
Number of subjects: 122
Study 18760123 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 500
Study 18760123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 16005384 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg of D‐amphetamine
Number of subjects: 32
Study 16005384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12404670 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 0
Study 12404670 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 12404670 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (paroxetine and citalopram)
Number of subjects: 0
Study 10624541 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS
Number of subjects: 13
Study 10624541 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 13
Study 10624541 — intervention group
Group type: COMPARATOR
Intervention: Placebo rTMS
Number of subjects: 13
Study 7729392 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative slope keyboard support system
Number of subjects: 0
Study 7729392 — intervention group
Group type: EXPERIMENTAL
Intervention: Full motion forearm supports
Number of subjects: 0
Study 7729392 — intervention group
Group type: COMPARATOR
Intervention: No arm support (control)
Number of subjects: 0
Study 2158260 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204,219 (40 mg oral dose)
Number of subjects: 18
Study 2158260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 335584 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA preparation
Number of subjects: 89
Study 335584 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oleic acid)
Number of subjects: 89
Study 335584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PUFA and placebo)
Number of subjects: 89
Study 31767368 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ST cluster
Number of subjects: 574
Study 31767368 — intervention group
Group type: COMPARATOR
Intervention: High ST cluster
Number of subjects: 574
Study 31767368 — intervention group
Group type: COMPARATOR
Intervention: Gamers cluster
Number of subjects: 574
Study 31767368 — intervention group
Group type: COMPARATOR
Intervention: High cellphone cluster
Number of subjects: 574
Study 30193936 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab (3 mg/kg IV) every 4 weeks for 52 weeks
Number of subjects: 2
Study 30193936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 28333534 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 276
Study 28333534 — intervention group
Group type: COMPARATOR
Intervention: Individual therapy (IT)
Number of subjects: 276
Study 26223506 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical agent A (20% aluminum chloride hexahydrate)
Number of subjects: 19
Study 26223506 — intervention group
Group type: COMPARATOR
Intervention: Topical agent B (1% aluminum acetate)
Number of subjects: 19
Study 23223947 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ropivacaine and 2 μg sufentanil in 30 mL 0.9% saline (Group B)
Number of subjects: 80
Study 23223947 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ropivacaine in 30 mL 0.9% saline (Group C)
Number of subjects: 80
Study 23223947 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg sufentanil in 30 mL 0.9% saline (Group D)
Number of subjects: 80
Study 23223947 — intervention group
Group type: COMPARATOR
Intervention: 30 mL of 0.9% saline (Group A)
Number of subjects: 80
Study 23223947 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (ropivacaine with sufentanil)
Number of subjects: 80
Study 23223947 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B, C, or D
Number of subjects: 80
Study 20850880 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 766
Study 18180761 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intensive cognitive-behavioral therapy (CBT)
Number of subjects: 10
Study 18180761 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (no treatment)
Number of subjects: 10
Study 17101026 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 105
Study 17101026 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 105
Study 14751554 — intervention group
Group type: EXPERIMENTAL
Intervention: Training at 10 degrees in the upper visual field
Number of subjects: 18
Study 14751554 — intervention group
Group type: EXPERIMENTAL
Intervention: Training at 10 degrees in the lower visual field
Number of subjects: 18
Study 14751554 — intervention group
Group type: COMPARATOR
Intervention: No-training control group
Number of subjects: 18
Study 11693075 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical Care (PhC)
Number of subjects: 735
Study 11693075 — intervention group
Group type: COMPARATOR
Intervention: Traditional pharmacy practice (Control)
Number of subjects: 735
Study 9383924 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions in pediatric psychology
Number of subjects: 0
Study 9383924 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive assessment of health and psychological outcomes
Number of subjects: 0
Study 9383924 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative treatment applications and strategies to integrate research and practice
Number of subjects: 0
Study 9383924 — intervention group
Group type: EXPERIMENTAL
Intervention: Case series to document promising methods
Number of subjects: 0
Study 9383924 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of costs versus benefits
Number of subjects: 0
Study 9383924 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials
Number of subjects: 0
Study 7523480 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody based kits
Number of subjects: 240
Study 7523480 — intervention group
Group type: COMPARATOR
Intervention: RIA
Number of subjects: 240
Study 7523480 — intervention group
Group type: COMPARATOR
Intervention: Monoclonal antibodies specific for the holohormone (anti-alpha beta)
Number of subjects: 240
Study 2464094 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (400 mg)
Number of subjects: 16
Study 2464094 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg)
Number of subjects: 16
Study 2464094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2464094 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (160 and 480 micrograms)
Number of subjects: 16
Study 30039790 — intervention group
Group type: EXPERIMENTAL
Intervention: Single quadrant injection technique (Group S)
Number of subjects: 57
Study 30039790 — intervention group
Group type: COMPARATOR
Intervention: Two quadrants injection technique (Group C)
Number of subjects: 57
Study 30039790 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative VAS after surgery
Number of subjects: 57
Study 27485318 — intervention group
Group type: EXPERIMENTAL
Intervention: OV/OB youth with asthma
Number of subjects: 142
Study 27485318 — intervention group
Group type: COMPARATOR
Intervention: OV/OB youth only
Number of subjects: 142
Study 26365445 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (twice weekly for 8 weeks)
Number of subjects: 30
Study 26365445 — intervention group
Group type: COMPARATOR
Intervention: Control (no anti-hypertensive treatment for 12 weeks)
Number of subjects: 30
Study 24262440 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab
Number of subjects: 1579
Study 24262440 — intervention group
Group type: EXPERIMENTAL
Intervention: Predefined cut points for predictive model
Number of subjects: 1579
Study 21175845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) bolus abciximab
Number of subjects: 355
Study 21175845 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) bolus abciximab
Number of subjects: 355
Study 18496310 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nasogastric feeding
Number of subjects: 70
Study 18496310 — intervention group
Group type: COMPARATOR
Intervention: Bolus nasogastric feeding
Number of subjects: 70
Study 18496310 — intervention group
Group type: COMPARATOR
Intervention: Bolus orogastric feeding
Number of subjects: 70
Study 16712437 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple No in smoking refusal
Number of subjects: 454
Study 16712437 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternatives in shoplifting refusal
Number of subjects: 454
Study 16712437 — intervention group
Group type: EXPERIMENTAL
Intervention: Declarative Statements in smoking refusal
Number of subjects: 454
Study 15742998 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 small polyethylene radiopaque cylinders (5 mm x 2 mm in diameter) with a standard solid meal (790 Kcal)
Number of subjects: 48
Study 11293461 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational model based on neuropsychological theory of category learning
Number of subjects: 0
Study 11293461 — intervention group
Group type: COMPARATOR
Intervention: Optimal decision rules (complex piecewise quadratic functions)
Number of subjects: 0
Study 9146775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg effervescent
Number of subjects: 12
Study 9146775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg effervescent
Number of subjects: 12
Study 9146775 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg capsules
Number of subjects: 12
Study 8190296 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (acute and chronic administration)
Number of subjects: 15
Study 8190296 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (after withdrawal)
Number of subjects: 15
Study 3064647 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 30 mg
Number of subjects: 60
Study 3064647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31951276 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating proportions of B cells
Number of subjects: 2774
Study 31951276 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating proportions of B cells among premenopausal women
Number of subjects: 2774
Study 31951276 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating proportions of monocytes among premenopausal women
Number of subjects: 2774
Study 31951276 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher monocyte proportions
Number of subjects: 2774
Study 31951276 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher B cell proportions
Number of subjects: 2774
Study 30835626 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-academic abilities
Number of subjects: 1034
Study 30835626 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation
Number of subjects: 1034
Study 30835626 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer relations
Number of subjects: 1034
Study 30835626 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental education
Number of subjects: 1034
Study 30835626 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion knowledge assessment
Number of subjects: 1034
Study 28335745 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (0.6%, 12 cm2, application duration: 15 min)
Number of subjects: 28
Study 28335745 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine (25/25 mg, 10 cm2, application duration: 60 min)
Number of subjects: 28
Study 28335745 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-application of Capsaicin and Lidocaine/Prilocaine (Cap/LA and LA/Cap)
Number of subjects: 28
Study 28335745 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-application of Capsaicin and Lidocaine/Prilocaine (LA/Cap)
Number of subjects: 28
Study 25647536 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 93
Study 25647536 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing soccer
Number of subjects: 93
Study 25647536 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study 23314743 — intervention group
Group type: EXPERIMENTAL
Intervention: LCI699 (0.5 mg b.i.d. for 14 days, then 1 mg b.i.d. for 15 days)
Number of subjects: 14
Study 23314743 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone (50 mg b.i.d., up-titrated to 100 mg b.i.d. in 12/14 patients)
Number of subjects: 14
Study 23314743 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone (50-100 mg b.i.d.)
Number of subjects: 14
Study 23314743 — intervention group
Group type: EXPERIMENTAL
Intervention: LCI699 (0.5-1 mg b.i.d.)
Number of subjects: 14
Study 22108151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin (10/20 or 10/40 mg)
Number of subjects: 1143
Study 22108151 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10, 20, or 40 mg)
Number of subjects: 1143
Study 22108151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin (10/20-40 mg)
Number of subjects: 1143
Study 22108151 — intervention group
Group type: COMPARATOR
Intervention: All doses (ezetimibe/simvastatin and atorvastatin)
Number of subjects: 1143
Study 19604319 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic intervention
Number of subjects: 40
Study 19604319 — intervention group
Group type: COMPARATOR
Intervention: Control condition (simple relaxation)
Number of subjects: 40
Study 19604319 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Hypnosis and Control)
Number of subjects: 40
Study 17197848 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% propofol
Number of subjects: 64
Study 17197848 — intervention group
Group type: COMPARATOR
Intervention: 1.0% propofol
Number of subjects: 64
Study 15166915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba special extract EGb 761 (2 x 120 mg/day for 7 days)
Number of subjects: 50
Study 15166915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11784875 — intervention group
Group type: COMPARATOR
Intervention: cisplatin and paclitaxel
Number of subjects: 1207
Study 11784875 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin and gemcitabine
Number of subjects: 1207
Study 11784875 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin and docetaxel
Number of subjects: 1207